Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OSE Immunotherapeutics SA

ose-immuno.com/en

Latest From OSE Immunotherapeutics SA

BI’s Business Development Focus Remains On Early Collaboration

Boehringer Ingelheim’s US business development head Ioannis Sapountzis outlines BI’s efforts to catch up with competitors in NASH and immuno-oncology via early-stage partnerships and licensing deals.

Business Strategies Research and Development Strategies

Deal Watch: Fresenius Drops Bid For Akorn, Citing Data-Integrity Concerns

Janssen and Bristol team to develop next-generation oral anticoagulant, while UCB buys Proximagen's nasal spray candidate and Duke spinout focused on genomics.
Business Strategies Deals

OSE Immunotherapeutics Adds Boehringer Ingelheim To Its Pharma Partnering List

Collaborating with the German family-controlled drug maker on OSE's novel checkpoint inhibitor aligns with French firm's strategy of partnering its portfolio candidates.

Analysis Business Strategies

OSE Immunotherapeutics Seeks Partner For Lead Drug

Emerging Company Profile: Alexis Peyroles, chief operating officer of OSE Immunotherapeutics outlines the 2016-founded company's plans for commercializing its lead drug, Tedopi (OSE-2102).

StartUps and SMEs ImmunoOncology
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • OSE Pharma SA
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • OSE Immunotherapeutics SA
  • Senior Management
  • Dominique Costantini, CEO
    Alexis Peyroles, COO, Head, Fin., Bus. Dev. & Operations
    Maryvonne Hiance, Chairman
    Bernard Vanhove, COO, R&D and Intl Scientific Collaborations
  • Contact Info
  • OSE Immunotherapeutics SA
    Phone: 2 28 29 10 10
    22, boulevard Benoni Goullin
    Nantes, 44200
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register